+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players

  • ID: 4699667
  • Report
  • Region: Global
  • 93 Pages
  • CBR Pharma Insights
1 of 4
Interest and Investment within the Field of Exosome Therapies have been Increasing Steadily Over the Past 10 Years

FEATURED COMPANIES

  • ArunA Biomedical Inc.
  • Ciloa
  • Codiak Biosciences Inc.
  • Evox Therapeutics Ltd
  • ReNeuron Group Plc
  • Stem Cell Medicine Ltd
  • MORE

Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players

Summary

Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine, cerebrospinal fluid (CSF) as well as in in vitro cell culture. These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right.

Exosome can be engineered to incorporate targeting ligands, allowing them to deliver cargo selectively to cells. Their small size allows them to penetrate the blood-brain barrier (BBB) for the delivery of central nervous system (CNS) therapies, whereas in cancer they can accumulate within the tumor via enhanced permeability and retention effects. Research within this area remains in the nascent stages, though several clinical studies have been registered within the field.

Although research within the exosome field is in the early stages, the area boasts a broad and diverse pipeline consisting of 22 active products. The majority of these products are within the Preclinical stage of development, and are indicated for the treatment of cancer. Other therapeutic areas strongly represented in this pipeline include the CNS and cardiovascular therapy areas. The clinical trials landscape for exosome therapies is similarly diverse. Since 2006, a total of 124 clinical trials have taken place.

As a result, interest and investment within the field of exosome therapies have been increasing steadily over the past 10 years. Currently there is only one product approved for use on the market, the Exodx Prostate Intelliscore diagnostic test for prostate cancer, developed and marketed by Exosome Diagnostics.

There are a range of companies within the pipeline landscape, most of which have only become established within the past few years. One of the leading companies in this sector is Capricor Therapeutics. The company is forecast to make a profit on the market with a net revenue of $333 million forecast for 2024 attributable to the anticipated successful development of its key product CAP-1002.

""Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players"", explores the application of Exosome technologies within the pharmaceutical and healthcare industries.

This report provides detailed information on the various healthcare applications of exosomes, and assesses the pipeline, clinical trial and company landscapes.

Scope

  • What are the features of the exosome lifecycle?
  • How are therapeutic exosomes prepared?
  • How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area?
  • Which companies are investing in exosome technologies?
  • How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors?

Reasons to buy

  • Develop a comprehensive understanding of exosome technologies and their potential for use within the healthcare sector.
  • Analyze the pipeline landscape and gain insight into the key companies investing in exosomes technologies.
  • Identify trends in interventional and observational clinical trials relevant to exosomes.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ArunA Biomedical Inc.
  • Ciloa
  • Codiak Biosciences Inc.
  • Evox Therapeutics Ltd
  • ReNeuron Group Plc
  • Stem Cell Medicine Ltd
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Exosomes in Healthcare
2.1 Overview of Exosomes
2.2 Drug Delivery Systems
2.2.1 Modified Release Drug Delivery Systems
2.2.2 Targeted Drug Delivery Systems
2.2.3 Liposomes
2.2.4 Viruses
2.2.5 Exosomes
2.3 The Exosome Lifecycle
2.4 Exosomes in Biology
2.5 Exosomes in Medicine
2.5.1 Biomarkers
2.5.2 Vaccines
2.6 Exosomes as a Therapeutic Target
2.7 Exosomes as Drug Delivery Vehicles
2.8 Therapeutic Preparation of Exosomes
2.8.1 Isolation and Purification
2.8.2 Drug Loading
2.8.3 Characterization
2.8.4 Bioengineering
2.8.5 Biodistribution and In Vivo Studies
2.8.6 Advantages of Exosome Therapies
2.8.7 Disadvantages of Exosome Therapies
2.9 Exosomes in Therapeutic Research
2.9.1 Exosome Gene Therapies
2.9.2 Exosome in Stem Cell Therapy
2.10 Exosomes in Oncology
2.10.1 Immunotherapy
2.10.2 Gene Therapy
2.10.3 Drug Delivery
2.10.4 Biomarkers
2.11 Exosomes in CNS Disease
2.11.1 Tackling the Blood-Brain Barrier
2.11.2 Exosomes in CNS Drug Delivery
2.11.3 Gene Therapy
2.12 Exosomes in Other Diseases
2.12.1 Cardiovascular Disease
2.12.2 Metabolic Disease

3 Assessment of Pipeline Product Innovation
3.1 Overview
3.2 Exosome Pipeline by Stage of Development and Molecule Type
3.3 Pipeline by Molecular Target
3.4 Pipeline by Therapy Area and Indication
3.5 Pipeline Product Profiles
3.5.1 AB-126 - ArunA Biomedical Inc.
3.5.2 ALX-029 and ALX-102 - Alxerion Biotech
3.5.3 Biologics for Autism - Stem Cell Medicine Ltd
3.5.4 Biologic for Breast Cancer - Exovita Biosciences Inc.
3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis - Regenasome Pty
3.5.6 Biologic for Lysosomal Storage Disorder - Exerkine
3.5.7 Biologics for Prostate Cancer - Cells for Cells
3.5.8 CAP-2003 - Capricor Therapeutics Inc.
3.5.9 CAP-1002 - Capricor Therapeutics Inc.
3.5.10 CIL-15001 and CIL-15002 - Ciloa
3.5.11 ExoPr0 - ReNeuron Group Plc
3.5.12 MVAX-001 - MolecuVax Inc.
3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke - Isfahan University of Medical Sciences
3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer - Codiak BioSciences Inc.
3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology - Evox Therapeutics Ltd
3.5.16 TVC-201 and TVC-300 - Tavec Inc.

4 Assessment of Clinical Trial Landscape
4.1 Interventional Clinical Trials
4.1.1 Clinical Trials by Therapy Type
4.1.2 Clinical Trials by Therapy Area
4.1.3 Clinical Trials by Stage of Development
4.1.4 Clinical Trials by Start Date and Status
4.2 Observational Clinical Trials
4.2.1 Clinical Trials by Therapy Type
4.2.2 Clinical Trials by Therapy Area
4.2.3 Clinical Trials by Stage of Development
4.2.4 Clinical Trials by Start Date and Status
4.2.5 List of All Clinical Trials

5 Company Analysis and Positioning
5.1 Company Profiles
5.1.1 Capricor Therapeutics Inc.
5.1.2 Evox Therapeutics Ltd
5.1.3 ReNeuron Group Plc
5.1.4 Stem Cell Medicine Ltd
5.1.5 Tavec Inc.
5.1.6 Codiak Biosciences Inc.
5.1.7 Therapeutic Solutions International Inc.
5.1.8 ArunA Biomedical Inc.
5.1.9 Ciloa

6 Appendix
6.1 References
6.2 Abbreviations
6.3 About the publisher 
6.4 Disclaimer

List of Tables
Table 1: Exosome Technologies, Global, Examples of Modified Release Dosage Systems, 2018
Table 2: Exosome Technologies, Global, Challenges and Opportunities in Drug Delivery, 2018
Table 3: Exosome Technologies, Global, Breakdown of Lipid-Based Drug Delivery Systems, 2018
Table 4: Exosome Technologies, Global, Types of Viral Vector for Gene Therapy Delivery, 2018
Table 5: Exosome Technologies, Global, Capricor Pipeline Products, 2018
Table 6: Exosome Technologies, Global, Capricor Clinical Trials, 2018
Table 7: Exosome Technologies, Global, Capricor Completed Deals, 2009-2018
Table 8: Exosome Technologies, Global, Evox Pipeline Products, 2018
Table 9: Exosome Technologies, Global, Evox, Completed Deals, 2018
Table 10: Exosome Technologies, Global, ReNeuron Pipeline Products, 2018
Table 11: Exosome Technologies, Global, ReNeuron Clinical Trials, 2010-2019
Table 12: Exosome Technologies, Global, ReNeuron Completed Deals, 2018
Table 13: Exosome Technologies, Global, Stem Cell Medicine Pipeline Products, 2018
Table 14: Exosome Technologies, Global, Stem Cell Medicine Completed Deals, 2018
Table 15: Exosome Technologies, Global, Tavec Pipeline Products, 2018
Table 16: Exosome Technologies, Global, Tavec Clinical Trials, 2018
Table 17: Exosome Technologies, Global, Tavec Completed Deals, 2018
Table 18: Exosome Technologies, Global, Codiak Biosciences Pipeline Products, 2018
Table 19: Exosome Technologies, Global, Codiak Biosciences Clinical Trials, 2018
Table 20: Exosome Technologies, Global, Codiak Biosciences Completed Deals, 2018
Table 21: Exosome Technologies, Global, Therapeutic Solutions International Pipeline Products, 2018
Table 22: Exosome Technologies, Global, Therapeutic Solutions International Clinical Trials, 2018
Table 23: Exosome Technologies, Global, Therapeutic Solutions International Completed Deals, 2018
Table 24: Exosome Technologies, Global, ArunA Biomedical Pipeline Products, 2018
Table 25: Exosome Technologies, Global, ArunA Biomedical Clinical Trials, 2018
Table 26: Exosome Technologies, Global, ArunA Biomedical Completed Deals, 2018
Table 27: Exosome Technologies, Global, Ciloa Pipeline Products, 2018
Table 28: Exosome Technologies, Global, Ciloa Completed Deals, 2018

List of Figures
Figure 1: Exosome Technologies, Global, Pipeline by Stage of Development and Molecule Type, 2018
Figure 2: Exosome Technologies, Global, Pipeline by Therapy Area, 2018
Figure 3: Exosome Technologies, Global, List of All Pipeline Programs Involving Exosomes, 2018 (part 1)
Figure 4: Exosome Technologies, Global, List of All Pipeline Programs Involving Exosomes, 2018 (part 2)
Figure 5: Exosome Technologies, Global, Clinical Trials by Study Design, 2006-2025
Figure 6: Exosome Technologies, Global, Interventional Clinical Trials by Therapy Type, 2006-2022
Figure 7: Exosome Technologies, Global, Interventional Clinical Trials by Therapy Area, 2006-2022
Figure 8: Exosome Technologies, Global, Interventional Clinical Trials by Stage of Development, 2006-2022
Figure 9: Exosome Technologies, Global, Interventional Clinical Trials by Year, 2006-2022
Figure 10: Exosome Technologies, Global, Observational Trials by Therapy Area, 2011-2025
Figure 11: Exosome Technologies, Global, Observational Trials by Therapy Area, 2011-2025
Figure 12: Exosome Technologies, Global, Observational Clinical Trials by Year, 2011-2025
Figure 13: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 1)
Figure 14: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 2)
Figure 15: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 3)
Figure 16: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 4)
Figure 17: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 5)
Figure 18: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 6)
Figure 19: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 7)
Figure 20: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 8)
Figure 21: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 9)
Figure 22: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 10)
Figure 23: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 11)
Figure 24: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 12)
Figure 25: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 13)
Figure 26: Exosome Technologies, Global, Company Analysis Matrix, 2018

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ArunA Biomedical Inc.
  • Capricor Therapeutics Inc.
  • Ciloa
  • Codiak Biosciences Inc.
  • Evox Therapeutics Ltd
  • ReNeuron Group Plc
  • Stem Cell Medicine Ltd
  • Tavec Inc.
  • Therapeutic Solutions International Inc.
Note: Product cover images may vary from those shown
Adroll
adroll